Table 2.

Summary of Growth Responses in LAGH Clinical Trials in Children with GHD

Drug	Dose (LAGH vs Daily rhGH)	Phase of Study	Annual Height Velocity on LAGH (cm/y)	Annual Height Velocity on daily rhGH (cm/y)
Declage (Eutropin Plus, LB03002)	0.5 mg/kg/wk vs 0.21 mg/kg/wk	Phase 3: 12-mo study + 12-mo uncontrolled extension (117)	Year 1: 11.63 ± 2.60	Year 1: 11.97 ± 3.09
			Year 2: 8.33 ± 1.92
				Year 2 (switched to LB3002): 7.28 ± 2.34
Jintrolong	0.2 mg/kg/wk vs 0.25 mg/kg/wk	Phase 3: 25-wk study (42)	13.41 ± 3.72	12.55 ± 2.99
TransCon GH (ACP-001)	0.24 mg/kg/wk vs 0.24 mg/kg/wk	Phase 3: 52-wk study (118)	11.2 ± 0.23	10.3 ± 0.30
Somapacitan (NNC0195-0092)	0.04 mg/kg/wk vs 0.08 mg/kg/wk vs 0.16 mg/kg/wk vs 0.24 mg/kg/wk of rhGH	Phase 2: 6-mo study (57)	0.04 mg/kg/wk: 8.0 ± 2.0	11.4 ± 3.3
			0.08 mg/kg/wk: 10.9 ± 1.9
			0.16 mg/kg/wk: 12.9 ± 3.5
GX-H9	0.8 mg/kg/wk vs 1.2 mg/kg/wk vs 2.4 mg/kg/wk vs 0.21 mg/kg/wk of rhGH	Phase 2: 6-mo results (119)	0.8 mg/kg/wk: 11.50	11.24
			1.2 mg/kg/wk: 11.54
			2.4 mg/kg/wk: 11.86
Somatrogon (MOD-4023)	0.25 mg/kg/wk vs 0.48 mg/kg/wk vs 0.66 mg/kg/wk vs 0.24 mg/kg/wk of rhGH	Phase 2: 12-mo study (71)	0.25 mg/kg/wk: 10.4 ± 2.6	12.5 ± 2.1
		Phase 3 study in children using weekly dosing of 0.66 mg/kg/wk (73)	0.48 mg/kg/wk: 11.0 ± 2.3
			0.66 mg/kg/wk: 11.9 ± 3.5
Somavaratan (VRS-317)	XTEN sequence: naturally occurring hydrophilic amino acids	Phase 3 trial discontinued (79)	9.44	10.70

Abbreviations: GHD, GH deficiency; LAGH, long-acting GH; rhGH, recombinant human GH.